Triggers $22-million Tranche of Venture Capital Funding
SUNNYVALE, Calif., March 31 /PRNewswire/ -- CardioMind, Inc., a developer of stents for small, difficult-to-treat blood vessels, announced today that it has begun a First-in-Human clinical trial of its drug-eluting stent. The CARE II trial, as it is called, began in February at St. Vincent's Hospital in Melbourne, Australia, and, so far, has led to successful implantations in 12 patients.
With a .014-inch crossing profile, the CardioMind stent, known as the Sparrow(TM) Drug-Eluting Coronary Stent System, is 70% smaller in diameter than any other currently-approved stent. It targets treatment of blood vessels smaller than 2.75 mm in diameter, which currently constitute nearly 40% of all stent implants. The tightness of fit of conventional stents, as well as their inflexibility and the forces delivered by balloon expansion, however, may contribute to increased vessel trauma, which in turn leads to less favorable long term results. Beyond the range of current stenting practice, moreover, the CardioMind stent may also find use in vessels smaller than 2.25 mm and thus expand by up to 20% the worldwide market for stents, now over $4-billion annually.
"We view the Sparrow system as a platform technology for a gentler stent delivery system that will both improve safety and efficacy for currently performed procedures and also extend treatment to new areas of the coronary, neurovascular and peripheral artery system," says Charles Maroney, President and CEO of CardioMind.
How the CardioMind Stent Works
The unique design of the CardioMind Sparrow stent permits it to travel
within the guidewire lumen to the site of the lesion. There the
cardiologist releases the stent and allows it to self-expand to the vessel
wall. By contrast, conventional balloon-expandable stents travel over
guidewires to the lesion, and thus, by their very design, occupy more
volume. The Sparrow stent als
|SOURCE CardioMind, Inc.|
Copyright©2008 PR Newswire.
All rights reserved